Shots:

• The companies collaborated to accelerate the discovery and development of novel therapies for patients with cancer indications.M2GEN will provide valuable patient-consented- de-identified clinical and genomic data to support Merck's oncology efforts
• The data will be accessed through M2GEN's ORIEN which is a network of 18 cancer centers across the US
• The collaboration provides utility in Merck's oncology development programs including indications for Keytruda (pembrolizumab)

 ­ Ref: PRNewswire | Image: Merck